We previously reported that the treatment of 3 human cancer lines with the MEK1/2 inhibitor, selumetinib (AZD6244, ARRY-142886), sensitized the cells to ionizing radiation (IR) (15). The gene discussed is MAP2K1; the disease is cancer.